Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Scrip Team
The financing, which brings the total raised by Juvenescence to $165m, comes as longevity R&D programs supported by the company move towards human testing.
The companies plan to use surrogate endpoint data to win approval to challenge Sanofi and Shire for the Fabry disease market.
The results move AstraZeneca closer to challenging AbbVie and Johnson & Johnson’s blockbuster Imbruvica in the blood cancer market.
The partnership gives the German major another potential source of drugs to treat cardiovascular, oncological and gynecological diseases.
The funding comes as the Dutch biotech closes in on a potential conditional approval and closure of its acquisition of CytoSen.
The open-label Phase IIb data link setrusumab, licensed from Novartis, to improvements in bone density, offering encouragement for Mereo ahead of a critical upcoming readout for its lead program.